Showing results (91-100 of 250) with videos related to

Sort By:
Pageof 25
Leukemia Research|March 2, 2016
T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significanceXiaohui Zhang, Lubomir Sokol, John M Bennett, et al.
JCO Clinical Cancer Informatics|May 9, 2024
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and MicrosimulationCaterina Gregorio, Marta Spreafico, Saverio D'Amico, et al.
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 24, 2026
Unique structural and ligand-binding properties of the Staphylococcus aureus serine hydrolase FphEJeyun Jo, Tulsi Upadhyay, Xiangyan You, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Unique structural and ligand binding properties of the Staphylococcus aureus serine hydrolase FphEJeyun Jo, Tulsi Upadhyay, Xiangyan You, et al.
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2014
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromesGuillermo Garcia-Manero, Hanna J Khoury, Elias Jabbour, et al.
JCO Precision Oncology|March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With RuxolitinibAndrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.
Pageof 25